2023年5月1日

Albatroz疗法——一个生物科技公司针对组织重塑阻止肿瘤生长和治疗关节炎——宣布,它已获得300万美元的资金由Outram生物和种子资金加快发展治疗性抗体一种新颖的目标降解细胞外基质,这是一个关键因素与癌症和关节炎。和该公司还收到安进第一金票奖在新加坡,承认科学与商业计划的可行性。癌症已经转移(扩散到身体的其他部位)很难治疗,占大多数的癌症死亡。和Albatroz已获得专有权非常具体和新目标,阻止肿瘤的生长和复发,包括一系列的治疗性抗体,抑制这一目标。期间研究所的分子和细胞生物学(IMCB),机构对科学技术和研究(A * STAR)在新加坡,弗雷德巴德博士,首席执行官和科学Albatroz创始人之一,发表突出控制蛋白质糖基化途径,使细胞外基质降解。和GalNAc-T激活的研究(晚会)糖基化途径发现了一个新的目标,后成为暴露在细胞表面糖基化。激活目标具体发生在肿瘤和关节炎滑液膜,结缔组织,行关节囊。加上Albatroz靶向抗体特异性高的这一目标有选择地减少细胞外基质降解同时最小化毒性。Albatroz也是第一个安进的“金票”在新加坡接受。安进公司评估和科学委员会的力量和新奇的科学原理,专业技能的领导下,公司的商业计划的可行性和授予Albatroz访问设备齐全,从NSG生物学实验室交钥匙,BSL-2认证实验室。 KEY QUOTES: “Degradation of the extracellular matrix is a critical component of both tumor growth and arthritis, however candidate drugs against this process have been limited in their use due to toxicity profiles. We are thrilled with the industry support that is allowing us to accelerate development of Albatroz’s novel therapeutic antibodies in order to move toward the clinic. We look forward to collaborating with pharmaceutical and biotech innovators in order to maximize the impact of this science.” Dr. Fred Bard, CEO and Scientific Co-Founder of Albatroz “Albatroz is building on careful, fundamental research comparing normal and cancer tissues, which led to the exciting discovery of a novel and broadly distributed target present on the surface of diverse solid tumors. The therapeutic antibodies that Albatroz has developed may prevent the growth and metastasis of these cancers. These first-in-class agents have enormous potential to improve our ability to treat patients with cancer.” David Virshup, Director of the Programme in Cancer and Stem Cell Biology (CSCB) and Professor at Duke-NUS Medical School “Amgen’s sponsorship of the Golden Ticket award with NSG Biolabs captures what it means to support early-stage startups in their acceleration of bioscience innovation while contributing towards Singapore’s growing biotech ecosystem. Having evaluated many strong entries from a diversity of startups, we are enthusiastic about the cancer therapy and anti-arthritic platform being developed by Albatroz Therapeutics and their continued progress in advancing novel therapies to improve the lives of patients with serious diseases. Congratulations to Albatroz Therapeutics.” Alan Russell, Ph.D., Vice President of Biologic Therapeutic Discovery at Amgen “Albatroz Therapeutics is an exciting example of the burgeoning biotech industry in Singapore– Southeast Asia’s largest biotech hub, and one that boasts cutting-edge research and attracts leading scientists from around the world. The company has a comprehensive IP portfolio around the use of the target signaling pathway to discover and develop therapeutic antibodies, based on research that has been developed over the last decade, and fills a critical gap for patients suffering from arthritis and specific types of cancer that have been historically difficult to treat.” Christopher Tan, Partner at Outram Bio, who has been appointed to Albatroz’s Board of Directors Trending on Pulse 2.0